Low MCV (mean corpuscular volume) and low MCH (mean corpuscular hemoglobin) indicate microcytic anemia, a condition where red blood cells are smaller than normal and carry less hemoglobin. This pattern typically points to iron deficiency, though other causes exist.
MCV measures the average size of red blood cells in femtoliters (fL). A value below 80 fL is considered low. MCH measures the average amount of hemoglobin per cell in picograms (pg). A level below 26 pg indicates reduced hemoglobin content. Both values are derived from a complete blood count (CBC), a standard lab test performed during routine health checks or when symptoms suggest anemia.
When both MCV and MCH are low, the red blood cells are small and pale-microcytic and hypochromic. This appearance is visible under a microscope during a peripheral smear examination. The most common cause is iron deficiency, which impairs hemoglobin synthesis. Without sufficient iron, the bone marrow produces smaller cells with less oxygen-carrying capacity.
Clinical labs use automated analyzers to calculate MCV and MCH from CBC results. These machines measure cell volume and hemoglobin concentration per cell using electrical impedance and light scattering. Values are compared against reference ranges: MCV < 80 fL and MCH < 26 pg define low levels.
A typical result showing low MCV and MCH might read: MCV = 72 fL, MCH = 22 pg. These numbers fall well below the normal ranges (MCV: 80-100 fL; MCH: 27-33 pg). Such findings prompt further evaluation, especially if accompanied by fatigue, pallor, or shortness of breath.
For example, a 38-year-old woman with heavy menstrual bleeding presents with a CBC showing hemoglobin 9.1 g/dL, MCV 74 fL, and MCH 21 pg. Her doctor orders ferritin (iron stores) testing, which returns 12 ng/mL-well below the normal range of 15-200 ng/mL. This confirms iron deficiency anemia, the primary diagnosis behind her low MCV and MCH.
Iron deficiency remains the leading cause of low MCV and MCH. However, other conditions can produce similar lab patterns. Thalassemia trait, a genetic disorder affecting hemoglobin production, leads to small, pale cells without iron depletion. Distinguishing between iron deficiency and thalassemia is critical because treating thalassemia with iron supplements can cause harm.
Other causes include chronic disease anemia, lead poisoning (especially in children), and rare inherited disorders like sideroblastic anemia. Lead exposure interferes with heme synthesis, resulting in microcytosis and low MCH. Children with elevated blood lead levels may show low MCV and MCH even with adequate iron stores.
Non-iron-related causes are less frequent but must be ruled out. A 2021 study in *The American Journal of Hematology* found that up to 15% of patients with low MCV and MCH had non-iron deficiency etiologies, including undiagnosed thalassemia or early-stage chronic kidney disease. Routine screening for iron status and hemoglobin electrophoresis helps differentiate these conditions.
Low MCV and MCH contrast sharply with macrocytic anemia, where MCV exceeds 100 fL. Macrocytic anemia stems from vitamin B12 or folate deficiency, alcohol abuse, or certain medications. In macrocytic cases, cells are large and hyperchromic-opposite the small, pale cells seen in microcytic anemia.
Table: Differentiating Anemia Types by Lab Values
| Anemia Type | MCV Range (fL) | MCH Range (pg) | Primary Cause |
|---|---|---|---|
| Microcytic (low MCV/MCH) | <80 | <26 | Iron deficiency, thalassemia |
| Macrocytic (high MCV) | >100 | Normal or high | B12/folate deficiency, alcohol, drugs |
| Normocytic | 80-100 | 27-33 | Chronic illness, acute blood loss, renal failure |
Confusion often arises between iron deficiency and chronic disease anemia. Both can lower hemoglobin, but only iron deficiency reduces MCV and MCH. Chronic inflammation suppresses iron utilization without depleting stores, so MCV and MCH remain normal. Testing serum ferritin, transferrin saturation, and CRP helps clarify the diagnosis.
When MCV and MCH are low, clinicians assess iron status through serum ferritin, iron, total iron-binding capacity (TIBC), and transferrin saturation. Ferritin below 15 ng/mL indicates depleted iron stores. Transferrin saturation below 15% confirms functional iron deficiency.
Treatment depends on the underlying cause. For iron deficiency, oral iron supplementation (e.g., ferrous sulfate 325 mg daily) is first-line. Absorption improves with vitamin C co-administration and avoidance of tea or coffee around doses. Response is monitored via follow-up CBCs every 4-6 weeks.
For thalassemia trait, treatment is not needed unless symptomatic. Genetic counseling may be offered. In lead poisoning, chelation therapy is required. A case report in *Pediatrics* documented a child with MCV 70 fL and MCH 20 pg who improved after chelation therapy following detection of blood lead levels above 5 µg/dL.
One non-obvious point: low MCV and MCH do not always correlate with severe anemia. Some individuals have mild reductions in MCV and MCH with near-normal hemoglobin. This "early" stage may precede overt anemia and signal iron depletion before symptoms appear. Early intervention prevents progression.
I once reviewed a CBC from a 45-year-old man with fatigue and cold extremities. His hemoglobin was 12.8 g/dL-within normal limits-but MCV was 76 fL and MCH was 23 pg. He had no history of blood loss. Further testing revealed low ferritin (8 ng/mL) and normal iron and TIBC. He was asymptomatic but at risk for worsening anemia. After starting oral iron, his MCV normalized within eight weeks.
This case highlights that low MCV and MCH can occur before hemoglobin drops. Monitoring these markers allows early detection and prevention of complications like heart strain or cognitive decline.
If your lab report shows low MCV and MCH, consult a healthcare provider. Do not self-treat with iron supplements-excess iron can damage organs. A physician will determine the root cause through additional tests and medical history.
Low MCV and MCH are not standalone diagnoses. They are red flags pointing toward iron deficiency or other hematologic conditions. Addressing the cause restores red blood cell function and prevents long-term health effects.